Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06783192 · ClinicalTrials.gov registry record · Phase 1
A Drug-Drug Interaction Study of MK 8527 With a Combined Oral Contraceptive (LNG/EE)
A Phase 1 study of Human Immunodeficiency Virus (HIV) and HIV Pre-exposure Prophylaxis, sponsored by Merck Sharp & Dohme.
- Completed
- Registry status
- Phase 1
- Development phase
- 14
- Enrollment target
- 1
- Study location
NCT06783192: Completed Phase 1 study of Human Immunodeficiency Virus (HIV) and HIV Pre-exposure Prophylaxis, sponsored by Merck Sharp & Dohme.
NCT06783192 is a Phase 1 study of Human Immunodeficiency Virus (HIV) and HIV Pre-exposure Prophylaxis that has completed, run by Merck Sharp & Dohme. The registered enrollment target is 14 participants, below the 508-participant average among 18 other Human Immunodeficiency Virus (HIV) trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06783192, a Phase 1 study of Human Immunodeficiency Virus (HIV) and HIV Pre-exposure Prophylaxis, has completed, sponsored by Merck Sharp & Dohme.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 14 participants
- Enrollment target
- 1
- Study location
Study Summary
This study is designed to assess the effect of a single dose of MK-8527 on the single-dose pharmacokinetics (PK) and the safety and tolerability of levonorgestrel/ethinyl estradiol (LNG/EE) in healthy adult postmenopausal or ovariectomized female participants.
Conditions Studied
Interventions
- DRUG MK-8527
- DRUG LNG/EE
Study Locations (1)
Florida
- QPS-MRA, LLC-Early Phase (Site 0001) - South Miami
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2023-08-14 |
| Est. Completion | 2023-10-11 |
| Phase | Phase 1 |
What the finished NCT06783192 record still lists
NCT06783192 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 14 participants, a relatively small participant target, below the 508-participant average among 18 other Human Immunodeficiency Virus (HIV) trials with a reported enrollment target (97% lower).
The record links to 2 conditions, with Human Immunodeficiency Virus (HIV) appearing as the primary indexed condition, and to 2 interventions - of which MK-8527 is the first listed.
NCT06783192 reports a single indexed study location in Florida.
Frequently Asked Questions
What is clinical trial NCT06783192 about?
NCT06783192 is a clinical study titled "A Drug-Drug Interaction Study of MK 8527 With a Combined Oral Contraceptive (LNG/EE)". This study is designed to assess the effect of a single dose of MK-8527 on the single-dose pharmacokinetics (PK) and the safety and tolerability of levonorgestrel/ethinyl estradiol (LNG/EE) in healthy adult postmenopausal or ovariectomized female participants.
What is the current status of trial NCT06783192?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 14 participants. The study started on 2023-08-14. Estimated completion is 2023-10-11.
What conditions does trial NCT06783192 study?
This clinical trial studies the following conditions: Human Immunodeficiency Virus (HIV), HIV Pre-exposure Prophylaxis.
What interventions are being tested in trial NCT06783192?
The interventions under investigation include: MK-8527 (DRUG), LNG/EE (DRUG).
Who is sponsoring clinical trial NCT06783192?
This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06783192 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Human Immunodeficiency Virus (HIV)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06783192's enrollment target sits among peer trials
14 18th of 18 higher than 1 of 18 other Human Immunodeficiency Virus (HIV) trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Human Immunodeficiency Virus (HIV) trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Assess the Acceptability of the Darunavir/Cobicistat (DRV/COBI) Fixed-dose Combination (FDC) Tablet in Human Immunodeficiency Virus (HIV)-1 Infected Children
COMPLETED · Phase 1
-
Safety, Tolerability, and Immunogenicity of ALFQ in a HIV Vaccine Containing A244 and B.65321 in Healthy Adults
COMPLETED · Phase 1
-
A Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of ABBV-181 (Budigalimab) in Adult Participants With Human Immunodeficiency Virus (HIV)-1
COMPLETED · Phase 1
-
Study to Assess Adverse Events and How Intravenous (IV) or Subcutaneous (SC) ABBV-382 Moves Through the Body of Adult Participants With Human Immuno-Deficiency Virus (HIV-1)
COMPLETED · Phase 1
-
Persuasive Health Communication Intervention for HIV/HCV
RECRUITING · NA
-
Quitting Matters Human Immunodeficiency Virus Hybrid Trial
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02523092 · 14 participants · Phase 4
Use of CXCL9 as a Biomarker of Acthar Efficacy
- NCT04263285 · 14 participants · NA
Treatment of Depression Post-SCI
- NCT04743271 · 14 participants · NA
Food and Circadian Timing
- NCT05065671 · 14 participants · Phase 1
Microbiome Derived Metabolism and Pharmacokinetics
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT06358040 · started 2026-10 · NA
Opioid Dispenser for Microdiscectomy/Laminectomy